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S348 Poster Session IIRisk factors for outcomeswere analyzed and includedHematopoi-
etic cell transplantation comorbidity index (HCT-CI) score (Sorror,
Blood 2005), relapse risk score (Kahl, Blood 2007) and risk stratifica-
tion by age groups.110 patients (69%) had low or standard relapse
risk score while 49 (31%) had high score. 26 patients (16%) had
HCT- CI score of 0, 48 patients (30%) had score of 1-2, 48(30%)
had score of 3-4 and 32 (20%) had score of 5 or above.
Increasing HCT-CI score had a significant impact on OS in both
univariate and multivariate analysis (p\0.05). HCT-CI of 1-2, 3-4
and 5 plus was prognostic for OS (HR 2.6, 2.9 and 3.6; p 5 0.006,
0.005 and 0.001 respectively).For PFS, high relapse risk score was
prognostic (HR 7.8, p 5 0.001) but increasing HCT-CI score lost
significance.Risk stratification by age groups (60-65, 66-70 and 70
plus) did not show any prognostic implication on either PFS or OS.
Our results support the use of RIC HCT as a potentially curative
treatmentmodality for elderly patients, and as well support the prog-
nostic value ofHCT-CI score. Elderly patients with high scores (.5)
may not benefit fromundergoingHCTevenwithRIC orNMHCT.
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BLAST PERCENTAGE PRIOR TO TRANSPLANTATION IS THE STRONGEST
PREDICTIVE FACTOR FOR SURVIVAL AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH MYELODYS-
PLASTIC SYNDROME (MDS)
Jimenez, A.M.1, Rich, E.S.1, Nathan, S.1, Maciejewski, J.1,
Shammo, J.M.1, Katz, D.1, Braun, E.1, Hashmi, S.2, Fung, H.C.1
1Rush University Medical Center, Chicago, IL; 2West Suburban Hospital,
Chicago, IL
Background: Allogeneic hematopoietic stem-cell transplantation
(HSCT) is the only curative treatment for patients (pts) with myelo-
dysplastic syndromes (MDS) or secondary acute myeloid leukemia
(sAML)with long-term survival rates between 25% and 70%.Disease
stage at timeof transplantationhasbeenstrongly correlatedwith trans-
plant outcomes; current data suggests that achieving a low pre-trans-
plant tumor burden is critical for a successful allograft. We sought
to retrospectively identify the relationship between pre-transplant
blast percentage and clinical outcomes following HSCT inMDS pts.
Methods: We conducted a retrospective review of pts with MDS
who received an allogeneic HSCT in our institution from 1998 to
2010. We previously reported the impact of clinical characteristics
and treatment on outcomes in this patient population.We quantified
the pre-transplant marrow burden on all pts with available pathol-
ogy. Bone marrow biopsy was performed prior to allogeneic
HSCT and pts’ blast burden was quantified as low or high on the ba-
sis of blast percentage (\5% or $5% respectively).
Results: 35 MDS pts were transplanted at our institution between
1998 and 2010. Median age was 51 years (range: 24-66); male to fe-
male ratio 1:1; matched related donor 46% (n5 16); matched unre-
lated donor 54% (n 5 19). Cytogenetic risk group by IPSS: good,
40% (n5 14), intermediate, 37% (n5 13), poor, 23% (n5 8). Graft
source was mobilized peripheral blood in 80% (n 5 28) and bone
marrow in 20% of pts (n5 7). Information on marrow blast percent-
age prior to transplant was available for 32 pts; survival was 53% at 1
year and 40% at 2 years in this group. Survival at one year was supe-
rior for pts with low blast burden compared to those with$5%blasts
(68% vs. 30%, respectively p: 0.036). Among the 17 pts alive at 1
year, 77% had low blast burden (vs. only 40% in those pts who didn’t
survive past day +365). Blast percentage prior to transplant also pre-
dicted for survival on multivariate analysis (p: 0.042).
Conclusions: Our retrospective analysis identified blast percentage
as an independent predictor of clinical outcomes in MDS pts under-
going HSCT. Our results are consistent with the current literature.
Prospective evaluation of multiple clinical variables in a larger patient
population is warranted to better characterize prognostic factors. The
role of cytoreductive therapy prior to transplant in order to achieve
a low blast burden should be further evaluated in this setting.
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THE EFFECT OF KIRS EXPRESSION PROFILE IN DONOR/RECIPIENT
PAIRS IN HLA IDENTICAL SIBLING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tang, X., Wei, X., Feng, Y., Zhu, Z., He, J., Xu, Y. First Affiliated Hos-
pital of Soochow University, Jiangsu Institute of Hematology, Suzhou,
Jiangsu, ChinaObjective: We investigated the distribution characteristics of KIRs
expression profile in donor/recipient pairs with acute leukemia (AL)
receiving HLA-identical sibling hematopoietic stem cell transplan-
tation (sib-HSCT). We further explored the effect of KIRs expres-
sion profile in donor/recipient pairs on clinical outcome.
Methods: The genotypes of donor/recipient KIRs were determi-
nated by polymerase chain reaction- sequence specific primer
(PCR-SSP) for 80 pairs of donor/recipient receiving HLA-identical
sibling hematopoietic stem cell transplantation.
Results: 1. In 80 pairs of donor/recipient: (i) the KIRs were com-
pletely identical in 57.5% of donor/recipient pairs; (ii) the donors’
KIRs contained the recipients’ in 13.75% pairs; (iii) the recipients’
KIRs contained the donors’ in 17.5% of pairs; (iv) the KIRs were
completely different in 11.25% pairs. The graft versus host (GVH)
direction KIR-matched group was 75%. The percentage of group
donor B/X and group donor A/A was 50%, respectively. 2.Compar-
ing the patients fromGVH direction KIR-matched and mismatched
group, the incidence of acute (a) GVHD was 60% and 30%, respec-
tively (p5 0.0222), and 2-year OS was 62.96% and 94.12%, respec-
tively (p 5 0.0492). Particularly, grade III-IV aGVHD rate of
KIR-matched group was higher than that of non-KIR matched
group(15% vs 0%). 3. Donor B/X group had a higher 2-year OS
and 2-year relapse-free survival (RFS) compared with donor A/A
group (89.23% vs 49.57%, p 5 0.0159, and 90% vs 59.71%, p 5
0.0239, respectively). Patients with three or less aKIRs had a lower
2-year OS (58.9% vs 92.44%, p 5 0.0338) and a lower RFS
(65.14% vs 92.59%, p 5 0.0398), compared with patients with
more aKIR.
Conclusions: Donor KIR genotype appears to have a direct impact
on aGVHD, OS and RFS. Therefore, donor KIR genotype should
be evaluated as an outcome predictor of the HLA-identical sib-
HSCT.390
COMPARABLE SURVIVAL AFTER UNRELATED AND RELATED ALLOGE-
NEIC STEM CELL TRANSPLANTATION PERFORMED AT COMMUNITY CAN-
CER CENTERS
Khaled, Y., Solh, M., Zehngebot, L., Zakari, A., Reynolds, R., Castillo, R.,
Alemany, C., Reddy, V. Florida Cancer Institute, Orlando, FL
The outcomes after unrelated donor hematopoietic stem cell
transplantation (MUD HCT) have improved over the past decade
with survival equivalent to related donors (RD) HCT. Although
MUD HCT is becoming more available in community cancer cen-
ters, there is very limited literature available about the outcomes of
MUDHCT outside the academic setting. To study the above ques-
tion, we performed a retrospective analysis of the outcomes of 56
consecutive patients that underwent HCT (30 MUD, 26 RD) be-
tween August 2007 and July 2010 at our community cancer center.
All patients had a minimum follow up of one year post HCT. There
was no statistical difference between MUD and RD recipients
(Table 1). Conditioning regimens used were Fludarabine/Melpha-
lan in 13 patients (3 MUD & 10 RD), Busulfan based in 28 patients
(19 MUD & 9 RD), Fludarabine/TBI in 10 patients (5 MUD & 5
RD), Cytoxan/TBI in 2 patients (1 MUD & 1 RD) and other in 3
patients (2 MUD & 1 RD). Graft versus Host Disease (GVHD)
prophylaxis regimens used were Tacrolimus/Methotrexate in FIC
HCT recipients and Cyclosporine/Mycophenolate mofetil in
RIC/NMA HCT recipients. MUD HCT recipients received addi-
tional Thymoglobulin (4.5 mg/Kg). Median time to neutrophils en-
graftment was 14 days for RD and 13 days for MUD. The
cumulative incidence of acute GVHD (grade I-IV) was 60% for
MUD and 54% for RD. The cumulative incidence of chronic
GVHD was comparable between both groups of 63% and 72%
for MUD and RD respectively.
With median duration follow up of 2 years, there was no statistical
difference in overall survival (OS) at one and 2 years of 57% and 40%
for MUD recipients versus 65% and 54% for RD recipients respec-
tively (p 5 0.48). Similarly, disease free survival (DFS) at 1 and 2
years was 50% and 36% versus 50% and 22% for MUD and RD re-
cipients respectively (p5 0.24). There were more relapses in RD re-
cipients with cumulative incidence of 34% and 59% at 1 and 2 years
respectively compared to 23% at 1 and 2 years in MUD recipients.
Non relapse mortality (NRM) at day 100 was 10% and 8% for
